Increase efficiencies and productivity by automating core reporting tasks for medical writing.
Automate core regulatory report documents across the CTD pyramid and dramatically accelerate submission timelines.
Claret Capital Partners has invested €10M in Yseop to support global expansion and accelerate development of its Generative AI platform. Yseop Copilot helps leading pharma companies like Eli Lilly and Novartis create compliant regulatory documentation faster and with greater consistency.
With 27,000+ reports generated per month, Yseop solidifies its leadership in regulatory automation ahead of its DIA 2025 showcase.
With Generative AI on AWS, Yseop is streamlining pharmaceutical processes to improve patient outcomes worldwide. Discover our story behind Europe’s breakthrough innovations with AWS Pioneers Project.
Yseop featured in the inaugural AWS Pioneers Project Read More »
Starting off the year strong, Yseop was shortlisted for the Global Business Tech Awards in 2025
Yseop Shortlisted for Global Business Tech Awards Read More »
Yseop wins the 2025 BIG Innovation Award, recognizing groundbreaking innovation in Generative AI.
Yseop Honored with Business Intelligence Group’s 2025 BIG Innovation Award Read More »
Milestones and partnerships showcase the company’s role as a trusted partner for AI-driven innovation in the pharmaceutical industry.
Yseop Kicks Off 2025 by Strengthening Its Leadership in Generative AI for Life Sciences Read More »
Explore how generative AI empowers medical writing and regulatory teams to streamline workflows, ensure accuracy, and accelerate drug development while maintaining compliance.
Yseop Copilot integrates with Veeva Vault RIM for one-click document generation in medical writing.
Cognizant’s AI and industry expertise, combined with Yseop’s generative AI platform, aims to improve the productivity of scientific writers across the life sciences value chain
Already a leading provider of Generative AI for life sciences, Yseop leverages AWS for greater scalability and the acceleration of new drug introductions